198 related articles for article (PubMed ID: 15553393)
21. Collaborative effort.
Novak K
Nat Rev Cancer; 2002 Sep; 2(9):638. PubMed ID: 12240637
[No Abstract] [Full Text] [Related]
22. [Administrative organization and responsibility].
Hilsted JC; Krogsgaard K
Ugeskr Laeger; 2003 Apr; 165(16):1641-2. PubMed ID: 12756816
[TBL] [Abstract][Full Text] [Related]
23. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
24. Study agreements and budgets.
McJilton JS
Epilepsy Res Suppl; 1993; 10():185-91. PubMed ID: 8251095
[No Abstract] [Full Text] [Related]
25. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
26. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
27. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
28. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
29. BIO and biogenerics.
Feldbaum CB
Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
[No Abstract] [Full Text] [Related]
30. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
31. Biopharmaceutical benchmarks.
Walsh G
Nat Biotechnol; 2000 Aug; 18(8):831-3. PubMed ID: 10932150
[No Abstract] [Full Text] [Related]
32. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
Asano K; Tanaka A; Sato T; Uyama Y
Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials in India.
Maiti R; M R
Pharmacol Res; 2007 Jul; 56(1):1-10. PubMed ID: 17391981
[TBL] [Abstract][Full Text] [Related]
34. A new colonialism?--Conducting clinical trials in India.
Nundy S; Gulhati CM
N Engl J Med; 2005 Apr; 352(16):1633-6. PubMed ID: 15843665
[No Abstract] [Full Text] [Related]
35. Productivity counts--but the definition is key.
Mervis J
Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
[No Abstract] [Full Text] [Related]
36. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
37. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
38. Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts.
Milne CP; Kaitin KI; Dimasi JA
Am J Ther; 2007; 14(3):231-4. PubMed ID: 17515695
[No Abstract] [Full Text] [Related]
39. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
40. [Clinical drug research in Denmark--as effective, harmless and cheap as possible].
Højgaard L
Ugeskr Laeger; 1994 Feb; 156(6):784-6. PubMed ID: 8016979
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
